INTELLIA THERAPEUTICS, INC. (NTLA) Return on equity 2016–2025
INTELLIA THERAPEUTICS, INC. (NTLA) return on equity by fiscal year — reported net income divided by year-end shareholders’ equity.
-61.5%FY2025 · since FY2016: -15.1% → -61.5%
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | -61.5% | -1.9 pp |
| FY2024 | -59.5% | -13.7 pp |
| FY2023 | -45.8% | -7.4 pp |
| FY2022 | -38.4% | -12.6 pp |
| FY2021 | -25.8% | -0.3 pp |
| FY2020 | -25.5% | +150.2 pp |
| FY2019 | -175.7% | -145.0 pp |
| FY2018 | -30.7% | -8.2 pp |
| FY2017 | -22.5% | -7.4 pp |
| FY2016 | -15.1% | — |
ROE = reported net income ÷ reported year-end shareholders’ equity for the same fiscal year. Heavy buybacks shrink equity and can push ROE very high (or negative-equity years drop out).
Source: SEC XBRL filings · For reference only · Not investment advice